ArticleNutrition & metabolism2025
Association of fructose-1,6-diphosphatase 1 with the progression of diabetic kidney disease.
Article in Nutrition & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Renal gluconeogenesis: a key metabolic hub in health and kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundDiabetic Kidney Disease (DKD) is one of the most serious complications of diabetes mellitus, and a main cause of end-stage kidney disease (ESKD). The identification of clinically applicable molecular biomarkers for monitoring DKD progression has become increasingly essential. In this study, we aim to investigate the relationship between the expression of fructose-1,6-bisphosphatase 1 (FBP1), a rate-limiting enzyme in gluconeogenesis, and DKD.
methodsA two-sample Mendelian randomization (MR) analysis was conducted using plasma protein quantitative trait loci data obtained from deCODE genetics and DKD genome-wide association study data acquired from the Finnish Biobank Alliance to assess the causal relationship between FBP1 and DKD. In parallel, a retrospective cohort study was performed involving 107 patients with biopsy-confirmed DKD, in which DKD progression was defined as a composite endpoint consisting of serum creatinine doubling or ESKD. For this endpoint, a predictive nomogram was subsequently developed.
resultsMR results suggested that a genetically predicted higher level of circulating FBP1 was associated with a low risk of DKD (OR 0.57, 95% CI 0.33-0.98; P = 0.04) in diabetic patients. The expression level of renal FBP1 decreased with the progression of DKD pathological stage. Its expression level was positively correlated with estimated glomerular filtration rate (eGFR) (r = 0.717, P < 0.001) and expression of renal carnitine palmitoyl transferase 1 A (a rate-limiting enzyme in fatty acid oxidation) (r = 0.745, P < 0.001). During a median follow-up of 26 months, 41 (38%) patients suffered from DKD progression. Multivariate Cox regression indicated that a reduced renal expression level of FBP1 was correlated with an increased risk of DKD progression (HR 0.325, 95% CI 0.107-0.986, P = 0.047). Finally, the integration of FBP1 with 24-h urine protein and eGFR into a nomogram significantly improved the prediction of 1-year and 3-year event-free survival in DKD (C-index: 0.871 vs. 0.794, P = 0.011), demonstrating its additive prognostic value.
conclusionsRenal FBP1 might be a potential biomarker reflecting the severity of renal function and kidney progression in biopsy-proven DKD stages II to IV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.